Stock Rich List
#726 on the corporate holders of 809 holders

RA Capital Healthcare Fund LP

Director at Tyra Biosciences; 10% owner at Hemab Therapeutics Holdings; Director at Cytek Biosciences.

$66.4M
in disclosed stock, +$1.0M (+1.59%) today
Market closed. Prices as of Nov 19, 4:04 PM ET
Rank
726th of 809
Companies held
1
Largest holding
ARTV, 100.0% of total
Latest SEC filing
Aug 24, 2026
Listed but not counted
$1.73B

What the $66.4M is made of

Holdings counted

All filings on SEC.gov
CompanyHow heldSharesPriceValueShare of totalReported
Artiva Biotherapeutics ARTV
Common Stock
Indirectly (see filing footnote)17,329,570$3.83$66.4M100.0%Form 4, Jul 31, 2026

Share counts are the amounts RA Capital Healthcare Fund LP reported owning after each line of their latest filing for that company, adjusted for any later stock splits. Values use the latest price. Methodology.

Reported but not counted

These shares appear on RA Capital Healthcare Fund LP's filings but are held for charities, by investment funds the insider manages, or could not be valued reliably. Insiders usually disclaim ownership of fund holdings beyond their personal stake.

CompanyHow heldSharesPriceValueShare of totalReported
Hemab Therapeutics Holdings COAG
Common Stock
Through RA Capital Management GP, LLC
Held by a company or fund the insider manages
6,372,170$39.86$254M—Form 4, May 12, 2026
Tyra Biosciences TYRA
Common Stock
Through RA Capital Management GP, LLC
Held by a company or fund the insider manages
10,096,004$19.73$199M—Form 4, Jun 9, 2025
Tyra Biosciences TYRA
Common Stock
Through RA Capital Healthcare Fund, L.P.
Held by a company or fund the insider manages
8,697,956$19.73$172M—Form 4, Nov 8, 2024
Enliven Therapeutics ELVN
Common Stock
Through RA Capital Management GP, LLC
Held by a company or fund the insider manages
3,220,825$46.41$149M—Form 4, Oct 24, 2022
Janux Therapeutics JANX
Common Stock
Through RA Capital Management GP, LLC
Held by a company or fund the insider manages
10,141,287$10.29$104M—Form 4, Jun 11, 2025
Cytek Biosciences CTKB
Common Stock
Through RA Capital Management GP, LLC
Held by a company or fund the insider manages
13,381,054$6.32$84.6M—Form 4, Mar 15, 2022
Vor Biopharma VOR
Common Stock
Through RA Capital Management GP, LLC
Held by a company or fund the insider manages
4,501,882$18.52$83.4M—Form 4, Aug 24, 2026
Mineralys Therapeutics MLYS
Common Stock
Through RA Capital Management GP, LLC
Held by a company or fund the insider manages
5,825,521$14.16$82.5M—Form 4, Mar 30, 2026
Solid Biosciences SLDB
Common Stock
Through RA Capital Management GP, LLC
Held by a company or fund the insider manages
11,897,896$6.44$76.6M—Form 3, Jun 22, 2026
PepGen PEPG
Common Stock
Through RA Capital Management GP, LLC
Held by a company or fund the insider manages
18,554,273$3.93$72.9M—Form 4, Sep 26, 2025
Cytek Biosciences CTKB
Common Stock
Through RA Capital Healthcare Fund, L.P.
Held by a company or fund the insider manages
11,082,163$6.32$70.0M—Form 4, Feb 28, 2022
SpyGlass Pharma SGP
Common Stock
Through RA Capital Management GP, LLC
Held by a company or fund the insider manages
2,054,678$30.78$63.2M—Form 4, Feb 9, 2026
Hemab Therapeutics Holdings COAG
Common Stock
Through RA Capital Management GP, LLC
Held by a company or fund the insider manages
1,009,052$39.86$40.2M—Form 4, May 12, 2026
Inhibikase Therapeutics IKT
Common Stock
Through RA Capital Management GP, LLC
Held by a company or fund the insider manages
25,000,000$1.30$32.5M—Form 3, Jul 10, 2026
Climb Bio CLYM
Common Stock
Through RA Capital Management GP, LLC
Held by a company or fund the insider manages
3,403,429$9.28$31.6M—Form 4, Jan 5, 2026
ARS Pharmaceuticals SPRY
Common Stock
Through RA Capital Management GP, LLC
Held by a company or fund the insider manages
8,556,774$3.36$28.8M—Form 4, Sep 21, 2023
ARS Pharmaceuticals SPRY
Common Stock
Through RA Capital Healthcare Fund, L.P.
Held by a company or fund the insider manages
8,365,465$3.36$28.1M—Form 4, Sep 21, 2023
Mineralys Therapeutics MLYS
Common Stock
Through RA Capital Management GP, LLC
Held by a company or fund the insider manages
1,867,229$14.16$26.4M—Form 4, Mar 27, 2026
Fulcrum Therapeutics FULC
Common Stock
Through RA Capital Management GP, LLC
Held by a company or fund the insider manages
6,053,960$3.71$22.5M—Form 4, Dec 8, 2025
Evommune EVMN
Common Stock
Through RA Capital Management GP, LLC
Held by a company or fund the insider manages
2,710,293$7.24$19.6M—Form 4, Feb 17, 2026
Hemab Therapeutics Holdings COAG
Common Stock
Through RA Capital Management GP, LLC
Held by a company or fund the insider manages
354,938$39.86$14.1M—Form 4, May 12, 2026
Acrivon Therapeutics ACRV
Common Stock
Through RA Capital Healthcare Fund, L.P.
Held by a company or fund the insider manages
7,914,206$1.40$11.1M—Form 4, Apr 11, 2024
Janux Therapeutics JANX
Common Stock
Through RA Capital Management GP, LLC
Held by a company or fund the insider manages
1,048,406$10.29$10.8M—Form 4, Jun 11, 2025
Inhibikase Therapeutics IKT
Common Stock
Through RA Capital Management GP, LLC
Held by a company or fund the insider manages
6,970,000$1.30$9.1M—Form 4, Jul 29, 2026
Tyra Biosciences TYRA
Common Stock
Through RA Capital Management GP, LLC
Held by a company or fund the insider manages
442,721$19.73$8.7M—Form 4, Nov 8, 2024
Freenome FRNM
Common Stock
Through RA Capital Management GP, LLC
Held by a company or fund the insider manages
750,000$9.93$7.4M—Form 3, Jul 20, 2026
Evommune EVMN
Common Stock
Through RA Capital Management GP, LLC
Held by a company or fund the insider manages
784,345$7.24$5.7M—Form 4, Feb 17, 2026
Werewolf Therapeutics HOWL
Common Stock
Through RA Capital Healthcare Fund, L.P.
Held by a company or fund the insider manages
5,076,685$0.99$5.0M—Form 4, Jun 11, 2026
ARS Pharmaceuticals SPRY
Common Stock
Through RA Capital Nexus Fund II, L.P.
Held by a company or fund the insider manages
902,904$3.36$3.0M—Form 4, Nov 8, 2022
Adicet Bio ACET
Common Stock
Through RA Capital Management GP, LLC
Held by a company or fund the insider manages
1,182,624$2.46$2.9M—Form 4, Feb 20, 2026
Adicet Bio ACET
Common Stock
Through RA Capital Management GP, LLC
Held by a company or fund the insider manages
959,028$2.46$2.4M—Form 3, Feb 17, 2026
AN2 Therapeutics ANTX
Common Stock
Through RA Capital Management GP, LLC
Held by a company or fund the insider manages
300,853$5.22$1.6M—Form 4, Aug 9, 2024
PepGen PEPG
Common Stock
Through RA Capital Management GP, LLC
Held by a company or fund the insider manages
207,672$3.93$816K—Form 4, Sep 26, 2025
Solid Biosciences SLDB
Common Stock
Through RA Capital Management GP, LLC
Held by a company or fund the insider manages
109,661$6.44$706K—Form 3, Jun 22, 2026
Acrivon Therapeutics ACRV
Common Stock
Through RA Capital Management GP, LLC
Held by a company or fund the insider manages
426,302$1.40$597K—Form 4, Apr 11, 2024
Jade Biosciences JBIO
Common Stock
Through RA Capital Management GP, LLC
Held by a company or fund the insider manages
36,796
split-adjusted
$15.06$554K—Form 4, Apr 28, 2025
Werewolf Therapeutics HOWL
Common Stock
Through RA Capital Management GP, LLC
Held by a company or fund the insider manages
361,229$0.99$356K—Form 4, Jun 11, 2026
Acumen Pharmaceuticals ABOS
Common Stock
Through RA Capital Management GP, LLC
Held by a company or fund the insider manages
1,300,034$0.19$251K—Form 4, Jun 4, 2025
Solid Biosciences SLDB
Common Stock
Through RA Capital Management GP, LLC
Held by a company or fund the insider manages
28,569$6.44$184K—Form 3, Jun 22, 2026
Acumen Pharmaceuticals ABOS
Common Stock
Through RA Capital Management GP, LLC
Held by a company or fund the insider manages
588,850$0.19$114K—Form 4, Jun 4, 2025
Mineralys Therapeutics MLYS
Common Stock
Through RA Capital Management GP, LLC
Held by a company or fund the insider manages
6,200$14.16$88K—Form 4, Feb 19, 2026
Wave Life Sciences WVE
Ordinary Shares
Through RA Capital Management GP, LLC
Held by a company or fund the insider manages
28,815$2.72$78K—Form 4, Aug 11, 2025
Janux Therapeutics JANX
Common Stock
Indirectly (see filing footnote)
Held by a company or fund the insider manages
6,250$10.29$64K—Form 4, Jun 11, 2025
Vor Biopharma VOR
Common Stock
Indirectly (see filing footnote)
Held by a company or fund the insider manages
1,500$18.52$28K—Form 4, Aug 24, 2026
Jade Biosciences JBIO
Common Stock
Through RA Capital Management GP, LLC
Held by a company or fund the insider manages
806
split-adjusted
$15.06$12K—Form 4, Apr 28, 2025
Jade Biosciences JBIO
Common Stock
Through RA Capital Management GP, LLC
Held by a company or fund the insider manages
254
split-adjusted
$15.06$4K—Form 4, Apr 28, 2025
Acumen Pharmaceuticals ABOS
Common Stock
Through RA Capital Management GP, LLC
Held by a company or fund the insider manages
12,800$0.19$2K—Form 4, Jun 4, 2025
KALA BIO KALA
Common Stock
Through RA Capital Management GP, LLC
Held by a company or fund the insider manages
94
split-adjusted
$3.02$283—Form 4, May 26, 2022

Open-market trades, last 12 months

DateTradeCompanySharesPriceValueFiling
Jul 31, 2026BoughtARTV24,944$9.93$248KView
Jul 29, 2026BoughtARTV20,824$9.99$208KView
Jul 17, 2026BoughtARTV7,882$8.95$71KView
Jul 16, 2026BoughtARTV152,472$8.93$1.4MView
Jun 11, 2026SoldHOWL17,437$0.38$7KView
Jun 11, 2026SoldHOWL245,066$0.38$93KView
Jun 10, 2026SoldHOWL42,872$0.37$16KView
Jun 10, 2026SoldHOWL3,051$0.37$1KView
Jun 9, 2026SoldHOWL345,235$0.37$128KView
Jun 9, 2026SoldHOWL24,565$0.37$9KView
May 12, 2026BoughtCOAG6,387$24.90$159KView
May 11, 2026BoughtCOAG25,720$25.00$643KView
May 11, 2026BoughtCOAG14,149$24.47$346KView
May 8, 2026BoughtCOAG1,483$24.98$37KView
May 7, 2026BoughtCOAG1,985$24.95$50KView
May 7, 2026BoughtCOAG7,921$24.34$193KView
May 6, 2026BoughtCOAG53,407$24.83$1.3MView
May 6, 2026BoughtCOAG14,611$23.77$347KView
May 5, 2026BoughtCOAG10,268$25.00$257KView
May 5, 2026BoughtCOAG87,143$24.59$2.1MView
May 4, 2026BoughtCOAG133,750$18.00$2.4MView
May 4, 2026BoughtCOAG2,541,250$18.00$45.7MView
Apr 10, 2026SoldVOR828$15.75$13KView
Apr 9, 2026SoldVOR135,201$16.59$2.2MView
Apr 8, 2026SoldVOR130,862$16.91$2.2MView

Nearby on the list

Full list
Nearby ranks
RankNameStock holdingsToday
723Drugs Made In America Acquisition II LLC
10% owner, Drugs Made In America Acquisition II
$68.8M+$134K (+0.20%)
724BRC Group Holdings, Inc.
10% owner, Babcock & Wilcox Enterprises
$67.9M−$3.9M (−5.46%)
725Bpifrance Investissement S.A.S.
Director, Pasqal Holding SA
$66.4M−$5.3M (−7.41%)
726RA Capital Healthcare Fund LP
Director, Tyra Biosciences
$66.4M+$1.0M (+1.59%)
727Alyeska Investment Group, L.P.
10% owner, FrontView REIT
$66.3M−$858K (−1.28%)
728Pioneer Acquisition 1 Sponsor Holdco LLC
10% owner, Pioneer Acquisition I
$65.9M$0 (0.00%)
729Rosalind Advisors, Inc.
Director, Delcath Systems
$65.2M−$1.6M (−2.34%)

Other Tyra Biosciences insiders

All TYRA insiders

Questions

How much stock does RA Capital Healthcare Fund LP own?

RA Capital Healthcare Fund LP holds $66,372,253 in listed stock based on SEC filings and current prices, mostly Artiva Biotherapeutics (ARTV). That ranks 726th on the Stock Rich List.

Is this RA Capital Healthcare Fund LP's net worth?

No. It counts only listed shares reported on SEC Forms 3, 4 and 5. Cash, private companies, real estate, options and holdings that don't need to be reported are not included, so total net worth is likely different.

When did RA Capital Healthcare Fund LP last buy or sell stock?

The most recent open-market trade on file is a purchase of 24,944 ARTV shares on Jul 31, 2026 at $9.93.

Files jointly with SEC filer 1384859, SEC filer 1619841.